Evidence map›Paper›PMID 27634976›Full record

Trial reportInternational journal of stroke : official journal of the International Stroke Society2017

ASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly.

Stephanie A Ward, Parnesh Raniga, Nicholas J Ferris, Robyn L Woods, Elsdon Storey, Michael J Bailey, Amy Brodtmann, Paul A Yates, Geoffrey A Donnan, Ruth E Trevaks and 4 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of stroke : official journal of the International Stroke Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Stephanie A Ward1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Parnesh Raniga3 Monash Biomedical Imaging & ARC Centre of Excellence for Integrative Brain Function, Monash University, Clayton, Australia.
Nicholas J Ferris3 Monash Biomedical Imaging & ARC Centre of Excellence for Integrative Brain Function, Monash University, Clayton, Australia.
Robyn L Woods1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Elsdon Storey1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Michael J Bailey6 Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Amy Brodtmann7 Behavioural Neuroscience, Florey Institute for Neuroscience and Mental Health, Melbourne Brain Centre, Heidelberg, Australia.
Paul A Yates8 Department of Aged Care Services, Austin Health, Heidelberg, Australia.
Geoffrey A Donnan9 The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.
Ruth E Trevaks1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Rory Wolfe1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Gary F Egan3 Monash Biomedical Imaging & ARC Centre of Excellence for Integrative Brain Function, Monash University, Clayton, Australia.
John J McNeil1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
(Joint Senior authorship); on behalf of the ASPREE investigator group
Monash University · AUFlorey Institute of Neuroscience and Mental Health · AUAustin Health · AUMonash Health · AU

Funding

ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Adam Salmon, Elena Volpi · 2015 to 2026
$14.1M
NIA NIH HHS P30 AG044271NIA NIH HHS U01 AG029824
6 · The paper itself

Abstract

Rationale Cerebral microbleeds seen on brain magnetic resonance imaging are markers of small vessel disease, linked to cognitive dysfunction and increased ischemic and hemorrhagic stroke risk. Observational studies suggest that aspirin use may induce cerebral microbleeds, and associated overt intracranial hemorrhage, but this has not been definitively resolved. Aims ASPREE-NEURO will determine the effect of aspirin on cerebral microbleed development over three years in healthy adults aged 70 years and over, participating in the larger 'ASPirin in Reducing Events in the Elderly (ASPREE)' primary prevention study of aspirin. Sample size Five hundred and fifty-nine participants provide 75% power (two-sided p value of 0.05) to determine an average difference of 0.5 cerebral microbleed per person after three years. Methods and design A multi-center, randomized placebo-controlled trial of 100 mg daily aspirin in participants who have brain magnetic resonance imaging at study entry, one and three years after randomization and who undergo cognitive testing at the same time points. Study outcomes The primary outcome is the number of new cerebral microbleeds on magnetic resonance imaging after three years. Secondary outcomes are the number of new cerebral microbleeds after one year, change in volume of white matter hyperintensity, cognitive function, and stroke. Discussion ASPREE-NEURO will resolve whether aspirin affects the presence and number of cerebral microbleeds, their relationship with cognitive performance, and indicate whether consideration of cerebral microbleeds alters the risk-benefit profile of aspirin in primary prevention for older people. Trial registration Australian New Zealand Clinical Trials Registry ACTRN12613001313729.

Indexed as

AgedAspirinBrainCerebral HemorrhageCognitionDouble-Blind MethodFibrinolytic AgentsHumansInternational CooperationMagnetic Resonance ImagingPatient SelectionRisk AssessmentSample SizeStrokeWhite MatterAspirinFibrinolytic AgentsaspirinCerebral microbleedscognitive declinedementiahealthy agingneuroimagingsmall vessel disease

Identifiers

PMID27634976
PMCPMC6764436
OpenAlexW2520700064

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.